No­var­tis los­es patent ap­peal for block­buster MS drug, open­ing the door to gener­ic ri­vals

A US ap­pel­late court ruled against Swiss megaphar­ma No­var­tis in a patent in­fringe­ment dis­pute over its block­buster mul­ti­ple scle­ro­sis drug Gilenya, mak­ing room for gener­ics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER